Our Past Projects
• MEDICAL Device Study
• Infectious diseases (Dengue, Zika, Influenza, COVID-19)
• Clinical pharmacology & pharmacogenetics programme
• Chronobiology sleep and circadian rhythm studies
Collaboration with Duke University
SingHealth IMU, Duke University's Clinical Research Unit (Carolina, USA) and Medanta IMU (India) have signed a memorandum of understanding to facilitate appropriate multi-site studies at the three institutions.
Project that has been initiated since its launch include:
• Microarray signatures to aspirin response study
• Olfactory Bulb Imaging using MRI machine
Collaboration with Industry
SingHealth IMU has collaborative agreements with most major pharmaceutical companies and CROs, including:
• Covance • Parexel • IQVIA • MSD • GlaxoSmithKline (GSK) • Novartis OTM • PPD • Servier • Arcturus Therapeutics | • Pfizer • Esai • Takeda/Millennium • Bayer • Boehringer Ingelheim • Sanofi • Fibrogen • AstraZeneca |
Site Inspections & Audits
SingHealth IMU has been inspected by the Health Sciences Authority of Singapore and audited by major pharmaceutical companies / CROs such as GSK, IQVIA, Celerion and is approved as a full clinical trial site.
© 2025 SingHealth Group. All Rights Reserved.